Helio Genomics: Eric Ariazi

Eric Ariazi has been appointed as chief development officer of Helio Genomics. He joins the Irvine, California-based cancer testing company after founding his own consulting firm, Biomarker Strategy Consulting. Before that, he was senior principal scientist in the department of translational medicine at ORIC Pharmaceuticals, where he led development of predictive and pharmacodynamic biomarkers for clinical-stage compounds. Previously, he held various positions at Freenome, where he was an early employee and spearheaded development of targeted cfDNA methylation sequencing assays. Prior to that, he was an assistant research professor at Fox Chase Cancer Center. Ariazi holds a PhD in cellular and molecular biology as well as human cancer biology from the University of Wisconsin Carbone Cancer Center.